At some point in the course of the COVID19 epidemic in Germany, the German Health Minister Jens Spahn[@bib1] proclaimed, "It is much more expensive to test too little than to test too much." From the time the first rash of cases manifested themselves, the German government made testing its prime concern. Germany\'s liberal testing policy and its relentless efforts to test its residents for SARS COV2 is perhaps one of the main reasons for its low per capita infections and low mortality rate and perhaps also the reason its healthcare infrastructure was spared the overwhelming deluge seen in other European countries.

WHO Director-General Dr Tedros Adhanom Ghebreyesus\'s opening remarks at the media briefing[@bib2] on COVID 19 on March 16, 2020 had a simple message for all countries: to 'test, test and test' to defeat Covid-19. Since then, this strategy has become crystallised into a truism. But, for weeks after that directive, particularly in India, there wasn\'t enough escalation in testing (followed by isolation and contact tracing), which should have been the backbone of our response.

This piece is meant as a commentary on the testing policy sired and stewarded in India by the Indian Council of Medical Research (ICMR), our apex body on research. The curious thing about the ICMR\'s guidelines on testing is that all documents issued on the subject are headlined as advisories. By definition, advisories don\'t have the same mandate as executive or juridical orders. They are meant to have the weight of recommendations and perhaps provide the template for optimal practice and standard of care. They have been instead used as instruments to systematically disincentivise testing in India, and also, in a way, to medically disenfranchise healthcare workers within their own institutions. Medical institutions and courts have questioned the statutory nature of these guidelines.[@bib3] To get around this, governments have issued executive orders[@bib4] ordering diagnostic facilities and institutions to only adhere to ICMR guidelines on testing.

Several state governments in India seem to have prioritized a warped notion of keeping the number of COVID cases down over public health and safety. The most prominent example of this was what transpired in Gujarat starting with the Gujarat government\'s circular disallowing private labs from testing.[@bib5] This had to be revoked after the Gujarat High Court\'s intervention. Then came an order necessitating permission from the chief district health officer (CDHO) or the medical officer of health (MOH) to clear the COVID 19 test in private labs once a doctor prescribed it. It again took the intervention of the Gujarat High Court following a plea moved by the Indian Medical Association (IMA), Gujarat unit, to reverse this policy. This was followed by another disconcerting circular that made it mandatory for COVID suspects to get hospitalised if they wanted to get tested,[@bib6] thereby putting immense strain on hospitals that were compelled to turn patients away or keep them waiting. It took a massive public outcry to repeal this order as well. The only conclusion one can draw from such impediments to testing (in the middle of an epidemic), is a strange fixation on the part of state governments to keep numbers down by limiting testing options.

In Mumbai, there have been instances of notices being issued to doctors invoking the Epidemic Diseases Act, 1897 and the Disaster Management Act, 2005, threatening them with the cancellation of their licence to practice for not adhering to ICMR guidelines. In some instances, violation of a proviso (compulsory physical examination of the patient before prescribing the test) not even in the ICMR guidelines has been used to threaten doctors with punitive action.[@bib7]

The ICMR[@bib8] and the central government[@bib9] have repeatedly denied the prevalence of community transmission in India and her cities six months after the index case was detected and more than three and a half months after international travel was banned. This is baffling to most experts who believe that no amount of semantic manoeuvring can allow for a change in the phase of transmission of the epidemic. The damage effected by this resistance is evidenced in the fact that throughout June when the epidemic was raging in many metropolitan areas overwhelming the healthcare infrastructure there, and the ICMR by its own admission had declared that the majority of the infected people were likely to be asymptomatic, it still disallowed testing asymptomatic patients seeking admission for other medical or surgical ailments. This, at the very least, should have been made the standard of care in hospitals to fortify segregation and safety of admitted patients and prevent intramural cross-infection. In surgical patients, this was of particular concern as recent evidence showed that the 30-day mortality in patients who tested positive for COVID was 23.8%; pulmonary complications occurred in 51.2%.[@bib10] It was seemingly catastrophic to operate in COVID times, especially during the surge. Various submissions and pleas were made to the ICMR by medical and surgical federations, citing this evidence to include this subset for testing, but there was no yielding on this matter.

On 23 June, when the case count in India reached 4,56,115, the ICMR amended the testing criteria to include symptomatic patients outside hotspots and containment zones.[@bib11] In the same circular asymptomatic high-risk patients seeking hospitalisation were allowed the Rapid Antigen test. Even now, on the day of writing this tract, RT-PCR testing is not permitted for pre-admission, pre-operative screening.

India ranks among the lowest in terms of tests per capita.[@bib12] Philippines, Malaysia, Rwanda and Cuba test more people per day per capita than India does. One fails to see the reasons for the unwillingness to widen the ambit of COVID testing or access to it. It cannot be a lack of testing capacity.

The Indian diagnostics manufacturing industry has the capacity to make 146 million RT-PCR test kits a month, or 4.87 million kits a day.[@bib13] Just one company, MyLab Discovery Solutions (from Pune), has the capacity of producing 2,00,000 RT-PCR test kits per day.[@bib14] To put this into perspective, a city the size of Delhi is currently testing about 20,000--25,000 individuals a day. What\'s unfortunate is that many domestic test-kit manufacturers are scaling down production and exhorting the central government to allow them to export these test kits, because demand in India is low.

The COVID19 test positivity rate is a vital indicator as it provides information on whether a community/city/state is conducting enough tests to find cases. A high test positivity rate signifies that a community is mainly testing floridly symptomatic patients and perhaps missing mild or asymptomatic cases. A low positivity rate indicates that a community is also testing patients with mild or no symptoms. The WHO has maintained that in countries that have conducted extensive testing for COVID-19, the test positivity rate should remain at 5% or lower for at least 14 days.[@bib15]

Nitin Pai et al. at the Takshashila Institution (an independent think tank and centre for research in public policy) have proposed that "every administration test a minimum of 2500 people per week, for every million of the population; until the test positivity rate is less than 1%. By this count, India ought to be testing a minimum of 4,60,000 people per day and should ramp up this number until the test positivity rate falls from the current 10% to less than 1%. This possibly means we should be testing a million or more people every day --- nearly four times as many as we are currently doing."

A proliferation of cases makes bad copy for politicians and administrators. Public health has to be prioritized over politics and the arbitrary chasing of numbers and targets to build a narrative of superiority over other countries/states/cities. This isn\'t a tournament. There\'s nothing to be gained by one-upping others on the dashboard. Reducing testing to reduce the number of cases has the effect of amplifying community transmission. It\'s only when communities test enough can we isolate individuals and limit transmission, thereby limiting the most indisputably critical adverse outcomes -- morbidity and mortality.
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